Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104326 | 0.87 | CYP2A6 (0.64) | CYP2A6CYP2B6CYP2E1DHODHCYP11B2 | |
| SCHEMBL753744 | 0.83 | CYP2A6 (0.55) | CYP2A6CYP2B6CYP2E1NPC1RAB9A | |
| SCHEMBL2217759 | 0.80 | CYP2A6 (0.62) | CYP2A6CYP2B6CYP2E1SMN1; SMN2CYP11B2 | |
| SCHEMBL968383 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1NPC1NFKB1 | |
| SCHEMBL22130223 | 0.79 | ALDH1A1 (0.56) | CYP2A6CYP2B6CYP2E1NPC1RAB9A | |
| SCHEMBL3831923 | 0.79 | CYP2A6 (0.57) | CYP2A6CYP2B6CYP2E1SMN1; SMN2CYP11B2 | |
| SCHEMBL30098437 | 0.79 | ALDH1A1 (0.56) | CYP2A6CYP2B6CYP2E1NPC1RAB9A | |
| SCHEMBL21410153 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1DHODHCYP11B2 | |
| SCHEMBL12947816 | 0.79 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1NPC1NFKB1 | |
| SCHEMBL15455285 | 0.77 | CYP2A6 (0.50) | CYP2A6CYP2B6CYP2E1DHODHCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | claimed |
| US-20260123282-A1 | POLYCYCLIC COMPOUND, LIGHT-EMITTING DEVICE AND ELECTRONIC DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2026-04-30 | — | — | US | disclosed |
| CN-119841870-A | Platinum complex derivative containing intramolecular high-entropy charge transfer and application thereof | 厦门大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-105237513-B | A kind of trinitrogenazole alcohol heteroaromatic ether derivative and its preparation method and application | 上海倚诺升生物医药科技有限公司 | 2018-01-23 | — | — | CN | disclosed |
| CN-105237513-A | Triazole aromatic alcohol heterocyclic ether derivative and preparing method and application thereof | SHANGHAI YINUOSHENG BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2016-01-13 | — | — | CN | disclosed |
| US-20150266818-A1 | COMPOUNDS AND THEIR SYNTHESIS | UCL BUSINESS PLC (GB) | 2015-09-24 | — | — | US | disclosed |
| US-20150266818-A1 | COMPOUNDS AND THEIR SYNTHESIS | UCL BUSINESS PLC (GB) | 2015-09-24 | — | — | US | disclosed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | disclosed |
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| EP-1919891-B1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7691885-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-1919891-A1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007116230-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2007-10-18 | — | — | WO | disclosed |
| US-20070155794-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-20070155794-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-20070155794-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| WO-2007027594-A1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027594-A1 | 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260123282-A1 | POLYCYCLIC COMPOUND, LIGHT-EMITTING DEVICE AND ELECTRONIC DEVICE | SCO2, RFC1, RFC2 | CYP2A6 1989/4885CYP2B6 1423/4885CYP2E1 53/4885 |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | GPR119, GPR39, GIPR | CYP2A6 1711/4885CYP2B6 1666/4885CYP2E1 2047/4885 |
| US-20150266818-A1 | COMPOUNDS AND THEIR SYNTHESIS | ARSA, CCNL2, ATXN2L | CYP2A6 998/4885CYP2B6 376/4885CYP2E1 643/4885 |
| US-20070155794-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | CYP2A6 1760/4885CYP2B6 1233/4885CYP2E1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.